Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose esketamine for perinatal depression after cesarean delivery
ChiCTR2500107385Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Guangdong Medical University
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in postpartum depression (PPD) and major depressive disorder (MDD) (2 arms), sponsored by Second Affiliated Hospital of Guangdong Medical University. Primary endpoint: Improvement rate of EPDS score within 30 days postpartum. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
postpartum depression (PPD)major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2500107385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107385.